Published in Prostate on December 27, 2011
Interleukin-17 promotes development of castration-resistant prostate cancer potentially through creating an immunotolerant and pro-angiogenic tumor microenvironment. Prostate (2014) 0.89
Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer. Prostate Cancer Prostatic Dis (2013) 0.87
A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy. Clin Genitourin Cancer (2013) 0.80
Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy. Cancers (Basel) (2017) 0.77
Androgen deprivation and immunotherapy for the treatment of prostate cancer. Endocr Relat Cancer (2017) 0.75
Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin (2011) 30.81
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol (2008) 8.95
Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol (2002) 8.73
B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature (2010) 3.24
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A (2001) 3.15
Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res (2008) 3.09
Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology (1988) 2.38
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell (2005) 2.37
Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol (2005) 2.31
Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol (2004) 1.71
Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev (2009) 1.68
Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods (2009) 1.48
The role of androgens and estrogens in the pathogenesis of experimental nonbacterial prostatitis. J Urol (1988) 1.32
Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantigen-specific T lymphocyte response. J Immunol (1997) 1.29
Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer (2009) 1.24
Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization. Prostate (2009) 1.19
CCL25 increases thymopoiesis after androgen withdrawal. Blood (2008) 1.11
Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses. Hum Immunol (2010) 1.08
Effect of transforming growth factor-beta 1 on proliferation and death of rat prostatic cells. Endocrinology (1990) 1.07
Expression of proinflammatory genes during estrogen-induced inflammation of the rat prostate. Prostate (2000) 1.04
Prostate cancer immunotherapy. Curr Opin Urol (2007) 1.00
Regulation of Apoptosis in the Prostate Gland by Androgenic Steroids. Trends Endocrinol Metab (1999) 0.98
Androgen deprivation boosts prostatic infiltration of cytotoxic and regulatory T lymphocytes and has no effect on disease-free survival in prostate cancer patients. Clin Cancer Res (2010) 0.97
17 beta-estradiol induced prostatitis in the rat is an autoimmune disease. J Urol (1996) 0.93
In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice. Cancer Res (2010) 0.91
Prostate autoimmunity: from experimental models to clinical counterparts. Expert Rev Clin Immunol (2009) 0.89
Update on prostate cancer vaccines. Cancer J (2011) 0.88
Immune signatures predict prognosis in localized cancer. Cancer Invest (2010) 0.88
Perinatal exposure to estrogenic compounds and the subsequent effects on the prostate of the adult rat: evaluation of inflammation in the ventral and lateral lobes. Reprod Toxicol (2000) 0.88
Stromal and epithelial cells from rat ventral prostate during androgen deprivation and estrogen treatment--regulation of transcription. Exp Clin Endocrinol (1993) 0.83
FLIP-ping out: death receptor signaling in the prostate. Cancer Biol Ther (2008) 0.81
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res (2009) 2.32
Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer. Cancer Res (2011) 1.66
The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer. Cancer Immunol Immunother (2012) 1.50
Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine (2005) 1.23
Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells. Cancer Immunol Immunother (2006) 1.20
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol (2007) 1.14
DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother (2010) 1.12
Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma. Cancer Immunol Immunother (2011) 1.11
Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. J Immunol (2012) 1.09
Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor. Prostate (2007) 1.09
Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses. Hum Immunol (2010) 1.08
The SSX family of cancer-testis antigens as target proteins for tumor therapy. Clin Dev Immunol (2010) 1.06
An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans. J Clin Invest (2009) 1.01
Identification of autoantibodies elicited in a patient with prostate cancer presenting as dermatomyositis. Int J Urol (2006) 1.01
HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother (2010) 0.99
Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells. J Immunother (2011) 0.97
Prioritization of cancer antigens: keeping the target in sight. Expert Rev Vaccines (2009) 0.96
Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer. Prostate (2007) 0.95
Current controversies in the management of biochemical failure in prostate cancer. Clin Adv Hematol Oncol (2012) 0.95
Endothelin receptor antagonists in cancer therapy. Cancer Invest (2007) 0.95
Humoral immune responses to testis antigens in sera from patients with prostate cancer. Cancer Immun (2006) 0.95
Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. Clin Cancer Res (2009) 0.94
Identification of antigen-specific IgG in sera from patients with chronic prostatitis. J Clin Immunol (2004) 0.93
Immunotherapy for prostate cancer - recent progress in clinical trials. Clin Adv Hematol Oncol (2007) 0.91
DNA vaccines for the treatment of prostate cancer. Expert Rev Vaccines (2010) 0.91
IgG responses to tissue-associated antigens as biomarkers of immunological treatment efficacy. J Biomed Biotechnol (2010) 0.90
Antigen-specific IgG elicited in subjects with prostate cancer treated with flt3 ligand. J Immunother (2005) 0.90
Newer therapies in advanced prostate cancer. Clin Prostate Cancer (2004) 0.90
Effects of a monoclonal anti-alphavbeta3 integrin antibody on blood vessels - a pharmacodynamic study. Invest New Drugs (2006) 0.89
MAD-CT-2 identified as a novel melanoma cancer-testis antigen using phage immunoblot analysis. J Immunother (2007) 0.88
GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther (2007) 0.88
Antibody responses to prostate-associated antigens in patients with prostatitis and prostate cancer. Prostate (2011) 0.86
CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells. Cancer Immunol Immunother (2011) 0.84
Antigen loss and tumor-mediated immunosuppression facilitate tumor recurrence. Expert Rev Vaccines (2012) 0.83
Immunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response. Oncoimmunology (2012) 0.83
A negative selection methodology using a microfluidic platform for the isolation and enumeration of circulating tumor cells. Methods (2013) 0.83
Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer. Prostate (2011) 0.81
A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors. Clin Cancer Res (2008) 0.81
Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens. Immunobiology (2003) 0.81
A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy. Clin Genitourin Cancer (2013) 0.80
Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes. Prostate (2011) 0.79
Monitoring regulatory immune responses in tumor immunotherapy clinical trials. Front Oncol (2013) 0.79
Vaccination using peptides spanning the SYT-SSX tumor-specific translocation. Expert Rev Vaccines (2012) 0.79
A phase I study of a DNA vaccine targeting prostatic Acid phosphatase in patients with stage D0 prostate cancer. Clin Genitourin Cancer (2005) 0.78
Prostate carcinoma in transgenic Lewis rats - a tumor model for evaluation of immunological treatments. Chin Clin Oncol (2013) 0.76
Sipuleucel-T: immunotherapy for advanced prostate cancer. Open Access J Urol (2011) 0.75
Methods for constructing and evaluating antitumor DNA vaccines. Methods Mol Biol (2009) 0.75
Identification of autoantibodies in a patient with testicular cancer and concurrent inflammatory bowel disease. J Clin Oncol (2010) 0.75